Daily Bulletin

Men's Weekly

.

  • Written by Pitch Engine
image

The analysts forecast global allergic rhinitis market to grow at a CAGR of 0.95% during the period 2016-2020.

Allergic rhinitis is caused by the interaction of airborne allergens with specific immunoglobulin E (IgE) type antibodies on the surface of mast cells. This interaction causes mast cells to release and synthesize chemicals, causing inflammation of the surrounding tissues. Typical symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion. Extranasal symptoms such as allergic conjunctivitis, itchy ears and palate, and asthma may also occur. Allergic rhinitis is treated using medications such as antihistamines, intranasal corticosteroids, or immunotherapies. Alternative forms of treatment are also employed in certain cases.

Covered in this report

The report covers the present scenario and the growth prospects of the global allergic rhinitis drugs market for the period 2016-2020. To calculate the market size, it considers revenue generated from the sales of prescription and off-label drugs used to treat allergic rhinitis.

The market is divided into the following segments based on geography:

The report, Global Allergic Rhinitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Purchase a copy of the report at http://www.sandlerresearch.org/purchase?rname=50874 .

Key vendors

  • AstraZeneca
  • GlaxoSmithKline
  • Meda Pharmaceuticals
  • Merck
  • Sanofi
  • UCB

Other prominent vendors

  • Adamis Pharmaceuticals
  • Alcon
  • Alergo Pharma
  • ALK-Abelló
  • Allergy Therapeutics
  • Almirall
  • Ampio
  • Anergis
  • Apotex
  • Ares Life Sciences
  • Array BioPharma
  • Aspen Pharmacare
  • Atopix Therapeutics
  • Barr Laboratories
  • Belcher Pharmaceuticals
  • Circassia Pharmaceuticals
  • Dainippon Sumitomo
  • DBV Technologies
  • Dr Reddy’s Laboratories
  • Eddingpharm
  • Genentech
  • Greer Laboratories
  • Hanmi Pharmaceuticals
  • Hisamitsu Pharmaceutical
  • Intas Pharmaceuticals
  • Kyowa Hakko
  • Lupin Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Nektar Therapeutics
  • Novartis
  • Nuvo Research
  • Nycomed
  • Omega Pharma
  • Ono Pharmaceuticals
  • Pfizer
  • Revance Therapeutics
  • Roxane Laboratories (Boehringer Ingelheim)
  • Shionogi
  • Stallergenes
  • Sun Pharmaceuticals
  • Takeda Pharmaceutical
  • Teva Pharmaceuticals
  • Verona Pharma
  • VentiRx Pharmaceuticals

Market driver

  • Increased prevalence of allergic rhinitis

Market challenge

  • Patent expiries and competition from generic drugs

Market trend

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
For more Information on the report, inquire at http://www.sandlerresearch.org/inquire-before-buying?rname=50874 .

About US:         

Sandlerresearch.org is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.

Authors: Pitch Engine

Read more http://www.pitchengine.com/pitches/d7abf83a-2bb0-4aaf-bb5d-03fe01f57504

Business News

The ultimate checklist for launching a digital-first business

If you’re launching a business in 2025, chances are it’s going to be digital-first. Whether you’re running an online store, offering consulting services, or building something entirely new, they all h...

Daily Bulletin - avatar Daily Bulletin

“SMBs Are Building the Future While Australia Sleeps” — Marc Degli on AI, Innovation, and What Needs to Change

Australia’s startup scene has been called “emerging” for a decade — but for many founders, it still feels stalled. Government funding is mired in bureaucracy. Investors hedge their bets on “safe” deal...

Daily Bulletin - avatar Daily Bulletin

Hydrogen Pipe Infrastructure: A Guide to Future Networks

As Australia moves towards a cleaner energy future, hydrogen is emerging as a key player. But how do we get this promising energy source from production facilities to where it's needed? The answer l...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals